Fig. 5

Prognostic association of plasma ctDNA in MCL patients. (A, B) Univariate Cox proportional hazard models for progression-free survival (A) or overall survival (B), based on baseline ctDNA levels and genomic features identified in plasma samples. (C-G) Kaplan–Meier survival curves showing the progression-free survival of patients stratified by ctDNA levels (using the median as cutoff) (C), TP53 mutations (D), TRAF2 mutations (E), and alterations in the BCR/TLR signaling pathway (F) and PI3K pathway (G). (H–L) Kaplan–Meier survival curves showing the overall survival of patients stratified by ctDNA levels (using the median as cutoff) (H), TP53 mutations (I), TRAF2 mutations (J), and alterations in the BCR/TLR signaling pathway (K) and PI3K pathway (L)